Compare Harley-Davidson Inc (HOG) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs McKesson Corporation — how do they compare? Harley-Davidson Inc trades at $27.42 (market cap $2.72B), while McKesson Corporation trades at $899.06 (market cap $102.58B). The key difference: McKesson Corporation is far larger — about 37.7× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays the higher dividend (2.82%). Which is the better fit depends on your goals.
| HOG | MCK | |
|---|---|---|
Market Cap | $2.72B | $102.58B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.03 | $995.69 |
52-Week Low | $17.19 | $659.01 |
Enterprise Value | $3.13B | $109.12B |
Dividend Yield | 2.82% | 0.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $26.01, up 1.21% daily, with a bullish technical signal from moving averages and a neutral RSI. The company reported Q2 2026 EPS of $0.75, beating estimates, and raised full-year guidance. Revenue has declined from $5.8B in 2022 to $4.5B in 2025, with net income margin at 4.78%. Valuation ratios appear attractive with a P/E of 14.45 and P/B of 0.87. Recent news highlights North American sales strength and a strategic shift to U.S. production.
The outlook is cautiously optimistic; earnings beat and raised guidance support upside, but declining revenue and margin pressures pose risks. Analyst consensus is mixed with a $26 price target. Key risks include competitive threats and raw material costs. The stock's valuation discount offers potential if turnaround efforts gain traction.
McKesson (MCK) trades at $869.58, down 0.14% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with revenue growth to $359.05B in 2025 and consistent earnings beats, including Q2 2026 EPS of $9.93 versus $9.56 expected. Valuation metrics like P/E of 23.33 and P/S of 0.26 indicate reasonable pricing relative to peers. Recent news highlights Q1 2027 results exceeding expectations and raised full-year guidance, driven by specialty drug and oncology growth.
Outlook remains positive with 80% analyst buy ratings and a $1,000 consensus price target, suggesting 15% upside. Risks include thin net margins of 1.12% and high liabilities at $76.83B, which could pressure equity during economic downturns. Investors should focus on execution of raised guidance and margin improvements from cost efficiencies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
